Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study
Anticancer Research · 2024
DOI: 10.21873/anticanres.16849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Jonathan Q Trinh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, U.S.A.; jtrinh@unmc.edu. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: The PACIFIC trial demonstrated improved survival in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following definitive concurrent chemoradiotherapy (CRT). This study sought to explore real-world outcomes with durvalumab consolidation therapy at our institution. PATIENTS AND METHODS: We retrospectively identified patients diagnosed with stage III NSCLC at our institution from January 2012 to January 2022. We created two cohorts: one who received durvalumab following definitive CRT and a historical one who did not. Primary outcomes of interest included median progression-free survival (PFS) and overall survival (OS). Additionally, we performed subgroup analysis on the durvalumab cohort to explore the associations between survival and time to durvalumab initiation, PD-L1 expression, and neutrophil-to-lymphocyte ratio (NLR). RESULTS: We identified 79 patients with locally advanced NSCLC who were not surgical candidates. Patients treated with durvalumab (n=44) had significantly improved survival compared to the historical cohort (n=35) including a median PFS of 17.4 months versus 8.0 months (p=0.0019) and a median OS of 37.0 months versus 17.0 months (log-rank p-value=0.07, Wilcoxon p-value=0.02). Within the durvalumab group, outcomes did not significantly differ between those who initiated therapy before or after 42 days of finishing CRT, between various PD-L1 expression levels, or between high or low NLR. CONCLUSION: Patients who received durvalumab as consolidation therapy following definitive CRT demonstrated significantly improved survival compared to a historical cohort who did not receive durvalumab. Furthermore, durvalumab appears to benefit patients regardless of time to initiation, PD-L1 expression, or NLR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, U.S.A.; jtrinh@unmc.edu.
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, U.S.A.
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, U.S.A.
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, U.S.A.
- Department of Internal Medicine, VA Nebraska Western Iowa Health System, Omaha, NE, U.S.A.
Zitieren
APA
Trinh, J. Q., Xiong, Y., Smith, L. M., Abughanimeh, O., Marr, A. S., & Ganti, A. K. (2024). Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study. Anticancer Research. https://doi.org/10.21873/anticanres.16849
Vancouver
Trinh JQ, Xiong Y, Smith LM, Abughanimeh O, Marr AS, Ganti AK. Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study. Anticancer Research. 2024. doi:10.21873/anticanres.16849
BibTeX
@article{Trinh2024,
author = {Trinh, Jonathan Q and Xiong, Ying and Smith, Lynette M and Abughanimeh, Omar and Marr, Alissa S and Ganti, Apar K},
title = {Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16849}
}
EUVIMED